stars 1 stars 2 stars 3

About Codiak BioSciences Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Codiak BioSciences Questions

The Codiak BioSciences annual revenue was $22.4 million in 2026.

Douglas Williams is the CEO of Codiak BioSciences.

4 people are employed at Codiak BioSciences.

Codiak BioSciences is based in Cambridge, Massachusetts.

The NAICS codes for Codiak BioSciences are [5417, 54, 541714, 54171, 541].

The SIC codes for Codiak BioSciences are [873, 87].

Top Codiak BioSciences Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users